Subtopic Deep Dive

ACMG Guidelines for Variant Pathogenicity
Research Guide

Q: What is the core ACMG/AMP framework?

Richards et al. (2015) define 28 criteria in 5 strength levels (PVS1-PS4, BA1-BS4) for 5 pathogenicity categories, applied to 1M+ ClinVar variants.

Q: What methods refine ACMG classifications?

Population data (gnomAD via MacArthur 2014), functional assays, and ClinVar submissions (Landrum 2015); reanalysis reclassifies 10-20% of VUS (Eggington 2013).

Q: Which papers established ACMG standards?

Foundational: Richards et al. (2015, 30K citations), MacArthur et al. (2014, 1.2K), Rehm et al. (2013, 907); cancer extension: Li et al. (2016, 1.8K).

Q: What are open problems in ACMG application?

VUS persistence (20-40%), ancestry biases (Walter 2015), CNV integration (Riggs 2019), and lab discordance (Brownstein 2014).

What is ACMG Guidelines for Variant Pathogenicity?

ACMG Guidelines provide standardized criteria for classifying the pathogenicity of genetic sequence variants in clinical diagnostics.

Jointly developed by the American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP), these guidelines outline 28 criteria across pathogenic, likely pathogenic, uncertain significance, likely benign, and benign categories (Richards et al., 2015; 30,258 citations). They incorporate population frequency, computational predictions, functional studies, and segregation data. Over 50 studies have validated and refined these rules using ClinVar submissions (Landrum et al., 2015).

Curated Papers

Key Challenges

Why It Matters

ACMG Guidelines enable consistent variant interpretation across labs, reducing diagnostic errors in rare diseases like cystic fibrosis (Castellani et al., 2008). ClinVar aggregates 1M+ submissions classified under these rules, supporting reanalysis that upgrades 10-20% of variants from VUS to pathogenic (Landrum et al., 2015). Cancer sequencing adopts adapted criteria, improving precision oncology reporting (Li et al., 2016). Copy-number variant standards extend ACMG to CNVs, aiding 5-10% of unresolved exome cases (Riggs et al., 2019).

Key Research Challenges

Variants of Uncertain Significance

VUS comprise 20-40% of clinical variant calls, delaying diagnoses (Richards et al., 2015). Reclassification efforts using functional assays reassign 15% of VUS (Eggington et al., 2013). Inter-lab discordance reaches 30% without unified evidence weighting (Brownstein et al., 2014).

Population Database Biases

gnomAD frequencies misclassify variants in non-European ancestries (MacArthur et al., 2014). UK10K data shows rare variants missed by small cohorts (Walter et al., 2015). Calibration requires diverse 10K+ genomes for allele frequency thresholds.

Functional Evidence Standardization

Assays like minigene splicing vary 2-fold across labs (Richards et al., 2015). ClinGen frameworks validate <10% of submissions with strong evidence (Landrum et al., 2015). Cancer-specific rules address tumor heterogeneity but lack germline integration (Li et al., 2016).

Essential Papers

Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology

Sue Richards, Nazneen Aziz, Sherri J. Bale et al. · 2015 · Genetics in Medicine · 30.3K citations

ClinVar: public archive of interpretations of clinically relevant variants

Melissa Landrum, Jennifer M. Lee, Mark J. Benson et al. · 2015 · Nucleic Acids Research · 2.8K citations

ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/) at the National Center for Biotechnology Information (NCBI) is a freely available archive for interpretations of clinical significance of variants fo...

Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer

Marilyn M. Li, Michael Datto, Eric J. Duncavage et al. · 2016 · Journal of Molecular Diagnostics · 1.9K citations

Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics

Sarah S. Kalia, Kathy Adelman, Sherri J. Bale et al. · 2016 · Genetics in Medicine · 1.7K citations

Technical standards for the interpretation and reporting of constitutional copy-number variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen)

Erin Rooney Riggs, Erica Andersen, Athena M. Cherry et al. · 2019 · Genetics in Medicine · 1.6K citations

The Human Gene Mutation Database: towards a comprehensive repository of inherited mutation data for medical research, genetic diagnosis and next-generation sequencing studies

Peter D. Stenson, Matthew Mort, Edward V. Ball et al. · 2017 · Human Genetics · 1.4K citations

Guidelines for investigating causality of sequence variants in human disease

Daniel G. MacArthur, Teri A. Manolio, David Dimmock et al. · 2014 · Nature · 1.3K citations

The discovery of rare genetic variants is accelerating, and clear guidelines for distinguishing disease-causing sequence variants from the many potentially functional variants present in any human ...

Reading Guide

Foundational Papers

Start with Richards et al. (2015) for 28 criteria; MacArthur et al. (2014) for causality guidelines; Rehm et al. (2013) for NGS standards—these form the core framework cited in 40K+ papers.

Recent Advances

Riggs et al. (2019) for CNV extensions; Li et al. (2016) for cancer adaptations; Landrum et al. (2015) for ClinVar validation with 1M+ variants.

Core Methods

Bayesian weighting of criteria (PVS1 strongest); population cutoffs (PM2: <0.00005); functional assays (PS3); segregation (PS4); tools like InterVar implement rules computationally.

How PapersFlow Helps You Research ACMG Guidelines for Variant Pathogenicity

Discover & Search

Research Agent uses searchPapers('ACMG variant reclassification ClinVar') to retrieve 50+ papers like Richards et al. (2015), then citationGraph to map 30K+ citing works and findSimilarPapers for ClinGen extensions (Riggs et al., 2019). exaSearch uncovers inter-lab studies like Brownstein et al. (2014).

Analyze & Verify

Analysis Agent runs readPaperContent on Richards et al. (2015) to extract 28 criteria tables, verifyResponse with CoVe against ClinVar submissions (Landrum et al., 2015), and runPythonAnalysis to compute VUS reclassification rates from HGMD data (Stenson et al., 2017) using pandas. GRADE grading scores evidence strength for PVS1 criteria.

Synthesize & Write

Synthesis Agent detects gaps in VUS functional data across 100 papers, flags contradictions in allele frequency cutoffs (MacArthur et al., 2014 vs. Walter et al., 2015), and uses latexEditText with latexSyncCitations for ACMG workflow diagrams via exportMermaid. Writing Agent compiles LaTeX reports with latexCompile.

Use Cases

"Compute VUS reclassification rates from ClinVar ACMG data"

Research Agent → searchPapers('ClinVar ACMG VUS') → Analysis Agent → readPaperContent(Landrum 2015) → runPythonAnalysis(pandas crosstab of pathogenicity changes) → CSV export of 15% upgrade stats.

"Draft LaTeX guideline for somatic variant ACMG rules"

Synthesis Agent → gap detection(Li 2016) → Writing Agent → latexEditText(ACMG/AMP cancer criteria) → latexSyncCitations(Richards 2015, Li 2016) → latexCompile → PDF with tiered evidence table.

"Find NGS pipelines implementing ACMG classification"

Research Agent → searchPapers('ACMG NGS pipeline') → Code Discovery → paperExtractUrls(Retterer 2015) → paperFindGithubRepo → githubRepoInspect → Python scripts for variant scoring.

Automated Workflows

Deep Research workflow scans 100+ ACMG papers via searchPapers → citationGraph → structured report with GRADE-scored criteria updates (Richards 2015 baseline). DeepScan applies 7-step CoVe to verify VUS stats from ClinVar (Landrum 2015) with runPythonAnalysis checkpoints. Theorizer generates hypotheses for ancestry-specific ACMG adjustments from UK10K data (Walter 2015).

Try Doxa for ACMG Guidelines for Variant Pathogenicity Research

Frequently Asked Questions

What is the core ACMG/AMP framework?

Richards et al. (2015) define 28 criteria in 5 strength levels (PVS1-PS4, BA1-BS4) for 5 pathogenicity categories, applied to 1M+ ClinVar variants.

What methods refine ACMG classifications?

Population data (gnomAD via MacArthur 2014), functional assays, and ClinVar submissions (Landrum 2015); reanalysis reclassifies 10-20% of VUS (Eggington 2013).

Which papers established ACMG standards?

Foundational: Richards et al. (2015, 30K citations), MacArthur et al. (2014, 1.2K), Rehm et al. (2013, 907); cancer extension: Li et al. (2016, 1.8K).